AUROBAC THERAPEUTICS

📍 BIO International Convention 2026 is almost here! AUROBAC is looking forward to joining the global biotech community in San Diego from June 22–25 and engaging with partners, innovators, and healthcare leaders from around the world. 🤝 Attending BIO 2026? Let's connect and meet in San Diego! https://lnkd.in/exzSzYt9 #BIO2026 #Biotech #BioTechnology #Pharma #AMR #AntimicrobialResistance #InfectiousDiseases #Sepsis #Partnering #HealthcareInnovation #LifeSciences #Networking #GlobalHealth #BusinessFranceNorthAmerica #ChooseFrance

AMR is already a health security crisis—not a distant threat. At AUROBAC, we are proud to support this call from BEAM Alliance and more than 50 organizations urging France to make antimicrobial resistance a priority during its G7 France Presidency in 2026. As highlighted by our CEO, Florence Sejourne, innovation against drug-resistant infections is urgently needed, but innovation alone is not enough. We need policies that reward innovation, accelerate patient access, and strengthen global preparedness. Read Florence Séjourné's post below and the full call-to-action published in Le Monde here: https://lnkd.in/eCX-4Us6 #AMR #AntimicrobialResistance #HealthSecurity #G7 #France2026 #Innovation #PublicHealth #BEAMAlliance

As a member of the BEAM Alliance, AUROBAC strongly supports the call to recognize antimicrobial resistance (AMR) as more than a healthcare challenge. AMR is increasingly a matter of health security, industrial resilience, and strategic sovereignty for Europe. The erosion of antimicrobial manufacturing capacity, growing supply chain dependencies, and the continued lack of sustainable incentives for innovation pose significant risks to Europe's preparedness and competitiveness. Addressing AMR requires coordinated action across health, industry, research, and security policies. Integrating AMR and biodefence into the European Competitiveness Fund and related initiatives would be an important step toward safeguarding critical capabilities and strengthening Europe's resilience. We encourage stakeholders across the ecosystem to engage with the recommendations outlined in the BEAM Alliance white paper. Read the full white paper: https://lnkd.in/eZFQNmFU #AMR #AntimicrobialResistance #Biodefence #HealthSecurity #EU #Biotech #Innovation #AMRInnovation

🌟 Team spirit in action at the AUROBAC seminar 🌟 It was a great opportunity to step away from our daily routines and come together to reflect on topics that are shaping our future: Artificial Intelligence, AUROBAC’s values, our ESG Charter, and the strength of teamwork. Through inspiring discussions, collaborative workshops, and team-building activities, we reinforced what makes AUROBAC unique: the commitment, expertise, and positive energy of our people. 🚀 A big thank you to everyone who contributed to making this seminar such a success! 🙏 Moments like these remind us that our greatest asset is our team. Looking forward to building the future together! #AUROBAC #Teamwork #AI #CompanyValues #TeamBuilding #CorporateSocialResponsibility #Innovation #TogetherWeGrow

📢 AUROBAC is gearing up for BIO International Convention 2026! We are excited to share that AUROBAC will be attending the BIO International Convention 2026, one of the most influential global gatherings for the biotechnology industry, bringing together innovators, entrepreneurs, investors, and healthcare leaders from across the world. 📅 June 22–25, 2026 📍 San Diego Convention Center, San Diego, CA, USA 🔗 https://lnkd.in/dKrXuHVa At AUROBAC, our mission is to develop innovative therapies targeting severe bacterial infections and their complications in acute care settings. BIO 2026 represents an outstanding opportunity for us to engage with partners, exchange expertise, and accelerate impactful collaborations that can advance patient care worldwide. We are also honored to join the French Pavilion, showcasing the strength, creativity, and scientific excellence of the French biotech ecosystem on the international stage. 👉 If you are attending, our Chief Business Officer, Julie Cervesi, would be delighted to connect: https://lnkd.in/exzSzYt9 #BIO2026 #Biotech #BioTechnology #Pharma #AMR #AntimicrobialResistance #InfectiousDiseases #Sepsis #Partnering #HealthcareInnovation #LifeSciences #Networking #GlobalHealth #BusinessFranceNorthAmerica #ChooseFrance

🌍 A major step forward in the global fight against AMR At the 79th World Health Assembly, World Health Organization Member States adopted the updated Global Action Plan on Antimicrobial Resistance (2026–2036), reaffirming antimicrobial resistance (AMR) as one of the world's most pressing health and development challenges. The new plan strengthens the One Health approach, recognizing that AMR affects not only human health but also animals, plants, food systems and the environment. It calls for coordinated action across sectors, with a strong focus on: ✅ Infection prevention and control ✅ Vaccination measures ✅ Responsible antimicrobial use ✅ Enhanced surveillance systems ✅ Innovation ✅ Sustainable financing ✅ International collaboration At AUROBAC, we welcome this renewed global commitment and the emphasis on innovation. Translating these commitments into measurable impact will require continued engagement from governments, researchers, healthcare professionals and industry. The challenge of AMR is global and so must be the response! #AMR #AntimicrobialResistance #OneHealth #GlobalHealth #PublicHealth #Innovation #WHO #WHA79 #AUROBAC

A strong and timely message from the BEAM Alliance. Antimicrobial resistance (#AMR) must now be recognized as a strategic challenge at the crossroads of health, defense, industrial resilience, and competitiveness. Supporting European biotech SMEs, securing and scaling EU-based manufacturing, and mobilizing private capital are essential to rebuilding a robust and sustainable antimicrobial ecosystem in Europe. AUROBAC THERAPEUTICS is proud to contribute to this collective effort, alongside partners committed to strengthening Europe’s preparedness and sovereignty in the face of current and future health and security threats.

📢 AUROBAC at ESCMID Global 2026! 🌍 We are happy to share that AUROBAC THERAPEUTICS will be attending ESCMID Global 2026, taking place in Munich from April 17–21. As a company dedicated to advancing solutions against antimicrobial resistance (AMR) and bacterial infections, AUROBAC is looking forward to learning from and connecting with leading international experts in infectious diseases and clinical microbiology. This event is a fantastic opportunity to: 💡 Exchange knowledge 🤝 Build new collaborations 🚀 Drive progress in the fight against AMR Together, we can help shape the next generation of anti-infective innovation. Will you be attending? We would love to connect! 😊 🔗 Discover more about AUROBAC THERAPEUTICS: https://aurobac-tx.com/ #ESCMIDGlobal2026 #InfectiousDiseases #AntimicrobialResistance #AMR #Microbiology #Networking

We are thrilled to see the European Commission, through the DG Health Emergency Preparedness and Response Authority (DG HERA) support both CARB-X and Global Antibiotic R&D Partnership (GARDP) to accelerate innovation in antimicrobial resistance. This new partnership is a strong signal of Europe’s continued commitment to tackling one of the most pressing global health threats, by strengthening the entire R&D continuum - from early-stage discovery supported by CARB-X to late-stage development and access enabled by GARDP. Driving the discovery and development of innovative therapies against severe bacterial infections is at the core of our mission at AUROBAC. We look forward to seeing how this strengthened global collaboration will further accelerate the delivery of much-needed solutions for patients.

AUROBAC is pleased to announce its participation in AntibioDEAL Days 2026, taking place on March 30–31 in Rennes, France. As part of the event, Antoine Villié, Director Data Science, will present: “Applying Machine Learning to Biotech R&D: A Case Study on Narrow-Spectrum Antimicrobial Peptide Discovery.” 📅 Date: March 31 🕒 Time: 14:00–15:40 📍 Session: Tackling Antibacterial Resistance: From Translational Research to Broader Strategies We look forward to engaging with fellow researchers and industry leaders to explore innovative approaches to combating antibacterial resistance. More information about the event: https://lnkd.in/eVxvAn6Q #AntimicrobialResistance #AMR #Biotech #MachineLearning #DrugDiscovery #Antibiotics #Innovation